scholarly journals Long-term clinical response to treatment and maintenance of localized aggressive periodontitis: a cohort study

2016 ◽  
Vol 44 (2) ◽  
pp. 158-168 ◽  
Author(s):  
Karina A. F. S. Miller ◽  
Luciana S. Branco-de-Almeida ◽  
Sandra Wolf ◽  
Nicole Hovencamp ◽  
Tina Treloar ◽  
...  
Keyword(s):  
Cohort Study ◽  
Clinical Response ◽  
Aggressive Periodontitis ◽  
Response To Treatment ◽  
Localized Aggressive Periodontitis

Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases

2000 ◽  
Vol 29 (4) ◽  
pp. 145-152 ◽  
Author(s):  
Michele D. Mignogna ◽  
Lorenzo Muzio ◽  
Roberto E. Mignogna ◽  
Roberto Carbone ◽  
Elvira Ruoppo ◽  
...  
Keyword(s):  
Clinical Response ◽  
Response To Treatment

scholarly journals Clinical and microbiological characterization of localized aggressive periodontitis: a cohort study

2014 ◽  
Vol 59 (2) ◽  
pp. 165-171 ◽  
Author(s):  
O Oettinger-Barak ◽  
MN Sela ◽  
H Sprecher ◽  
EE Machtei
Keyword(s):  
Cohort Study ◽  
Aggressive Periodontitis ◽  
Localized Aggressive Periodontitis

scholarly journals Treatment of localized aggressive periodontitis alters local host immunoinflammatory profiles: A long‐term evaluation

2020 ◽  
Author(s):  
Luciana S. Branco‐de‐Almeida ◽  
Yenisel Cruz‐Almeida ◽  
Yandy Gonzalez‐Marrero ◽  
Rachad Kudsi ◽  
Izabel C. V. Oliveira ◽  
...  
Keyword(s):  
Aggressive Periodontitis ◽  
Local Host ◽  
Term Evaluation ◽  
Localized Aggressive Periodontitis

scholarly journals 3424 Serial Biomarker Monitoring Predicts Long Term Outcomes in Acute Graft Versus Host Disease

2019 ◽  
Vol 3 (s1) ◽  
pp. 114-114
Author(s):  
Hrishikesh Krishna Srinagesh ◽  
Hrishikesh Krishna Srinagesh ◽  
Urvi Kapoor ◽  
Mina Aziz ◽  
Kaitlyn Ben-David ◽  
...  
Keyword(s):  
Regression Model ◽  
Clinical Response ◽  
Corticosteroid Therapy ◽  
Acute Gvhd ◽  
Accurate Determination ◽  
Immunosuppressive Treatment ◽  
Response To Treatment ◽  
Training Set ◽  
Validation Set

OBJECTIVES/SPECIFIC AIMS: The first aim of the study is to evaluate the accuracy of serum biomarkers of acute GVHD measured after four weeks of corticosteroid therapy to predict 6 month NRM. The second aim of this study is to compare the accuracy of the biomarker algorithm to that of clinical response to corticosteroids after four weeks. The third aim of the study is to develop a novel regression model that uses weekly biomarker measurements over the first month of corticosteroid therapy to predict 6 month NRM. METHODS/STUDY POPULATION:. Patients who received HCT at one of 22 IRB-approved centers and provided blood samples to the Mount Sinai Acute GVHD International Consortium (MAGIC) biorepository and developed GVHD between January 2008 to May 2018 are included in this study. Patients were divided by time into a training set (Jan 2008-Dec 2015, n=233) for model development and a validation set (Jan 2015-May 2018, n=357) to evaluate the predictive performance of the model. The later time of the validation set was chosen deliberately to model contemporaneous GVHD treatment practices. The size of each group was designed so that there would be roughly equal numbers of deaths in both groups. RESULTS/ANTICIPATED RESULTS:. Serum concentrations of GVHD biomarkers after one month of corticosteroid therapy were measured in the validation set, and the predicted probability of NRM ($\hat{\rm p}$) was computed according to the previously published algorithm: $\log[-\log(1 - \hat{\rm p})]=-11.263 + 1.844({\rm logST}2)+ 0.577({\rm logREG}3\alpha)$. The performance of the biomarker algorithm was evaluated by creating receiver operating characteristic (ROC) curves and calculating the area under the curve (AUC) in the validation set. The AUC of the biomarker algorithm was a significantly better predictor of 6 month NRM than clinical response to treatment after four weeks of corticosteroids (0.84 vs. 0.64, p<0.001), which is a clinically relevant improvement in accuracy. To evaluate serial biomarker monitoring, serum biomarker concentrations will be measured weekly at five time points from treatment initiation to one month after corticosteroid therapy. We will use these values in the training set to develop a regression model for 6 month NRM that accounts for repeated biomarker measurements. The performance of this model will be tested in the validation set and the accuracy of the serial biomarker measurements will be compared to the accuracy of measuring biomarkers at the single time point after four weeks of corticosteroid therapy. An AUC improvement of 0.05 would be considered clinically significant. DISCUSSION/SIGNIFICANCE OF IMPACT: Clinical response to treatment after four weeks has been the standard endpoint in GVHD interventional trials for decades. If biomarkers measured at the same time more accurately predict long term mortality, this study would provide the basis for a novel endpoint in GVHD trials and enable more accurate determination of effect size of experimental interventions. An accurate biomarker algorithm will prove useful in guiding immunosuppressive treatment decisions for patients with GVHD. Patients identified by the algorithm as low-risk may benefit from reduced-dose corticosteroid therapy, potentially reducing lethal opportunistic infections. Patients identified as high-risk will be candidates for more intensive immunosuppression or investigational therapies. This precision medicine approach tailors therapy to the individual patient’s biology.

HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study

2017 ◽  
Vol 21 (3) ◽  
pp. 295-301 ◽  
Author(s):  
Marina Talamonti ◽  
Marco Galluzzo ◽  
Arianna Zangrilli ◽  
Marina Papoutsaki ◽  
Colin Gerard Egan ◽  
...  
Keyword(s):  
Cohort Study ◽  
Clinical Response ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Adalimumab Treatment

scholarly journals Local and Plasma Biomarker Profiles in Localized Aggressive Periodontitis

2017 ◽  
Vol 2 (3) ◽  
pp. 258-268 ◽  
Author(s):  
L.S. Branco-de-Almeida ◽  
Y. Cruz-Almeida ◽  
Y. Gonzalez-Marrero ◽  
H. Huang ◽  
I. Aukhil ◽  
...  
Keyword(s):  
Gingival Crevicular Fluid ◽  
Aggressive Periodontitis ◽  
Response To Treatment ◽  
Diagnostic Tools ◽  
Tissue Destruction ◽  
Plasma Biomarker ◽  
Therapeutic Decisions ◽  
The Future ◽  
Localized Aggressive Periodontitis ◽  
Inflammatory Profile

Localized aggressive periodontitis (LAP) patients possess a systemic hyperinflammatory response after lipopolysaccharide stimulation. However, the levels of inflammatory and bone biomarkers in plasma, as well as possible associations between local and plasma biomarkers, are unknown in LAP. This cross-sectional study aimed to characterize gingival crevicular fluid (GCF) and plasma biomarker profiles in LAP patients, their healthy siblings (HS), and healthy unrelated controls (HC). Fifty-eight LAP subjects, 33 HS, and 49 HC (African Americans, aged 5 to 25 y) were included. Following collection of clinical parameters with GCF and plasma samples, levels of 16 inflammatory and bone resorption biomarkers were determined with Milliplex. Univariate and correlation analyses were performed among all clinical and laboratorial parameters. Discriminant analyses were used to investigate groups of biomarkers discriminating LAP from HS and HC in GCF and plasma. GCF levels of multiple cytokines and chemokines and RANKL:OPG ratio (receptor activator of nuclear factor kappa-B ligand:osteoprotegerin) were higher in LAP disease, most of which positively correlated with probing depth and attachment loss of sampled sites. A group of IL-12p40, IL-6, IL-12p70, IL-2, and MIP-1α discriminated LAP diseased sites from twheir healthy sites, as well as from HS and HC healthy sites. In plasma, only RANKL levels were increased in LAP versus controls, which positively correlated with the percentage of affected sites and deep/bleeding sites. A plasma inflammatory profile including MIP-1α, IL-8, IL-10, and INF-γ could significantly discriminate LAP patients from HS and HC. No correlations were found between GCF and plasma levels of biomarkers. In conclusion, an inflammatory profile including groups of specific biomarkers in GCF and plasma may significantly discriminate LAP from healthy individuals. The hyperinflammatory response previously found in the peripheral blood of LAP patients is dependent on lipopolysaccharide stimulation, apparently resulting mostly in local tissue destruction and changes in biomarker profile, with a slight influence in the systemic inflammatory profile ( ClinicalTrials.gov NCT01330719). Knowledge Transfer Statement: The results of this study can be possibly used by clinicians in the future as diagnostic tools for localized aggressive periodontitis. Thus, in the future, with proper consideration of cost, patient preference, chair-side feasibility and ultimately further studies validating the role of GCF markers for disease progression and response to treatment, this information could lead to more appropriate therapeutic decisions and the development of preventive approaches for susceptible patients.

Sign in / Sign up

Export Citation Format

Share Document